Based on the key measurements obtained from Vaccinex's financial statements, Vaccinex may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Vaccinex's Common Stock is fairly stable compared to the past year. Property Plant Equipment is likely to rise to about 451.1 K in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 234.7 K in 2024. Key indicators impacting Vaccinex's financial strength include:
The essential information of the day-to-day investment outlook for Vaccinex includes many different criteria found on its balance sheet. An individual investor should monitor Vaccinex's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Vaccinex.
Net Income
(21.26 Million)
Vaccinex
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Investments
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Long Term Debt
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Short Long Term Debt
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Common Stock
Property Plant Equipment
Net Invested Capital
Net Working Capital
Capital Lease Obligations
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Vaccinex Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Vaccinex's financial statements are interrelated, with each one affecting the others. For example, an increase in Vaccinex's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Vaccinex's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaccinex. Check Vaccinex's Beneish M Score to see the likelihood of Vaccinex's management manipulating its earnings.
Vaccinex Stock Summary
Vaccinex competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D . Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York. Vaccinex operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Comparative valuation techniques use various fundamental indicators to help in determining Vaccinex's current stock value. Our valuation model uses many indicators to compare Vaccinex value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vaccinex competition to find correlations between indicators driving Vaccinex's intrinsic value. More Info.
Vaccinex is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Vaccinex's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vaccinex's earnings, one of the primary drivers of an investment's value.
Vaccinex Systematic Risk
Vaccinex's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vaccinex volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Vaccinex correlated with the market. If Beta is less than 0 Vaccinex generally moves in the opposite direction as compared to the market. If Vaccinex Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vaccinex is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vaccinex is generally in the same direction as the market. If Beta > 1 Vaccinex moves generally in the same direction as, but more than the movement of the benchmark.
Vaccinex Thematic Clasifications
Vaccinex is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Vaccinex Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vaccinex's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Vaccinex growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Vaccinex help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vaccinex. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vaccinex based on widely used predictive technical indicators. In general, we focus on analyzing Vaccinex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vaccinex's daily price indicators and compare them against related drivers.
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.